P-006 Prognostic value of TP53 gene mutations in higher-risk MDS treated with azacitidine (AZA)

Bally, Cécile; Adès, Lionel; Renneville, Aline; Mozziconacci, Marie‐Joëlle; Preudhomme, Claude; DeThé, H.; Lehmann‐Che, Jacqueline; Fenaux, Pierre

doi:10.1016/s0145-2126(13)70055-9

Search citation statements

Order By: Relevance

Paper Sections

Select...

Positive Negative1

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2014

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Mutations in TET2 [65,73] Mutations in TP53 [74] Mutations in EZH2 [73,75] Abnormal/complex karyotype [13] Decreased methylation of the promoter region of PI-PLCbeta1 [69] Expression levels of BCL2L10 [14] BM, bone marrow; ECOG PS, Eastern Cooperative Oncology Group performance status.…”

Section: Positive Negativementioning

confidence: 99%

Minimizing risk of hypomethylating agent failure in patients with higher-risk MDS and practical management recommendations

et al. 2014

View full text Add to dashboard Cite

In Europe, azacitidine is the only hypomethylating agent approved for the treatment of patients with int-2-/high-risk myelodysplastic syndromes, offering significantly improved survival compared with conventional care. However, not all patients treated with azacitidine respond to treatment, and the vast majority of responders subsequently relapse. Currently, no standard care regimens have been established for patients after failure of azacitidine. Here, we discuss treatment options after loss of response or progression on azacitidine. In addition, we briefly consider optimization of first-line treatment along with potential biomarkers for identifying and monitoring response during treatment with azacitidine.

show abstract